← Back to Screener
Azitra Inc (AZTR)
Price$0.21
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-50.31%
Price vs S&P 500 (4W)-11.77%
VGM Score37.91
Market Capitalization$3.42M
All Metrics
Book Value / Share (Quarterly)$0.65
P/TBV (Annual)0.82x
Revenue Growth (3Y)-59.15%
Cash Flow / Share (Quarterly)$-0.66
Price vs S&P 500 (YTD)-28.70%
Net Profit Margin (TTM)-1721.97%
EPS (TTM)$-2.06
10-Day Avg Trading Volume0.51M
EPS Excl Extra (TTM)$-2.06
EPS (Annual)$-2.25
ROI (Annual)-273.18%
Net Profit Margin (5Y Avg)-26947.34%
Cash / Share (Quarterly)$0.62
ROA (Last FY)-218.00%
EBITD / Share (TTM)$-1.33
ROE (5Y Avg)-197.36%
Operating Margin (TTM)-1772.18%
Cash Flow / Share (Annual)$-1.05
P/B Ratio0.33x
P/B Ratio (Quarterly)0.36x
Net Income / Employee (Annual)$-842,700
EV / Revenue (TTM)-15.99x
Net Interest Coverage (TTM)-66.81x
ROA (TTM)-178.15%
EPS Incl Extra (Annual)$-2.25
Current Ratio (Annual)2.83x
Quick Ratio (Quarterly)6.59x
3-Month Avg Trading Volume8.65M
52-Week Price Return-88.34%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.63
P/S Ratio (Annual)455.76x
Asset Turnover (Annual)0.00x
52-Week High$2.40
Operating Margin (5Y Avg)-32140.94%
EPS Excl Extra (Annual)$-2.25
CapEx CAGR (5Y)-35.68%
26-Week Price Return-38.92%
Quick Ratio (Annual)2.07x
13-Week Price Return15.10%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)6.94x
Enterprise Value$-6.53M
Asset Turnover (TTM)0.07x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-119446.13%
Cash / Share (Annual)$0.19
3-Month Return Std Dev155.33%
Net Income / Employee (TTM)$-606,700
ROE (Last FY)-288.21%
Net Interest Coverage (Annual)-66.64x
EPS Basic Excl Extra (Annual)$-2.25
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.06
Receivables Turnover (Annual)0.00x
ROI (TTM)-267.46%
P/S Ratio (TTM)8.37x
Pretax Margin (5Y Avg)-26922.75%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.32
Price vs S&P 500 (52W)-115.39%
Year-to-Date Return-17.67%
5-Day Price Return-5.22%
EPS Normalized (Annual)$-2.25
ROA (5Y Avg)-159.41%
Net Profit Margin (Annual)-119566.53%
Month-to-Date Return-5.22%
Cash Flow / Share (TTM)$-1.76
EBITD / Share (Annual)$-2.22
Operating Margin (Annual)-146468.53%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-190.52%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.06
P/TBV (Quarterly)0.37x
P/B Ratio (Annual)0.75x
Pretax Margin (TTM)-1717.73%
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)4.60%
Beta-1.29x
Revenue / Share (TTM)$0.00
ROE (TTM)-284.75%
52-Week Low$0.10
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.25est. -0.01
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AZTRAzitra Inc | — | — | D | $0.21 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Azitra Inc is a clinical-stage biopharmaceutical company developing engineered microbial and protein therapeutics for rare dermatological diseases. Its proprietary platform identifies and genetically engineers naturally occurring bacteria to create live biotherapeutics, recombinant proteins, and small molecules for precision skin disease treatment. The company's pipeline includes ATR-12 for Netherton syndrome, ATR-04 for papulopustular rash, and ATR-01 for ichthyosis vulgaris.